VACCELERATE

The New European Vaccine Research Network

WHO WE ARE

Clinical research network for the coordination & execution of COVID-19 vaccine trials
Currently 214 clinical trial sites in 30 European countries
Involved academic institutions: University Hospital Cologne as lead & 26 national partners in 16 EU & 5 EU-associated countries
Funded by the European Commission with currently 12 Mio. €
Part of the European Commission's activities in future pandemic preparedness, including the "HERA Incubator", in analogy to U.S. BARDA

OUR MISSION

Serve as single-entry point for all stakeholders in COVID-19 vaccine development (pharma, academia, European Commission, EMA, ECDC, national health authorities and others) for phase 2 and 3 trials in Europe
Address any research question of interest outside the big registration trials, such as vaccine efficacy in virus variants, trials in children, pregnant women, immuno-compromised patients, trials on combination of different vaccines etc.

CURRENT ACTIVITIES

Capacity mapping of new clinical trial sites & laboratories with standardised methods for harmonised vaccine trials
Implementation of standardized educational measures, training & quality management for clinical trial sites
Harmonisation of data acquisition across all network sites, thus facilitating open data exchange for valid data analysis
Set-up of volunteer registries for vaccine trials for fast & efficient recruitment (>19,000 volunteers in Germany alone, expansion to more countries ongoing)

CONTACT & INFORMATION

Main primary contact through: info@vaccelerate.eu

Twitter: @vaccelerate_eu

Version: 19/02/2021